Approximately 25% of patients with the X-linked bleeding disorder hemophilia A (factor VIII, FVIII, deficiency) form inhibitory antibodies (inhibitors) to FVIII protein during replacement therapy. This evidence concerns the gene F8 and hemophilia A.